左归丸对原发性骨质疏松症2年的应时治疗评价  

Evaluation of Zuogui Wan Efficacy in the 2-years Seasonal Treatment for Primary Osteoporosis

作　　者：李鸿泓[1,2] 潘贵春 曹玉华[1] 

机构地区：[1]北京市石景山区中医医院,北京100043 [2]北京市八角社区卫生服务中心,北京100043

出　　处：《辽宁中医药大学学报》2015年第7期160-162,共3页Journal of Liaoning University of Traditional Chinese Medicine

摘　　要：目的：观察左归丸应时治疗原发性骨质疏松症的临床疗效。方法：选取2012年2月—2013年10月确诊为原发性骨质疏松症的患者68例,随机分为3组,应时治疗组25例采用立冬至大寒服用左归丸3个月,非应时治疗组21例于非冬季时段服用左归丸3个月,对照组22例（C组）在确诊后即采用福善美（阿仑磷酸钠）连续治疗3个月;第2年各组维持原方案治疗3个月。计算每年疗程结束后的证候积分,并测定腰椎L2~L4、髋部的骨密度,对三组治疗效果进行评价。结果：当年治疗3个月后证候积分下降差异显著,应时治疗组优于非应时治疗组（P〈0.05）,而与对照组相比无显著差异（P〉0.05）,但骨密度改善方面仍以对照组为优（P〈0.05）;第2年维持原方案治疗3个月后,应时治疗组证候积分下降最显著（P〈0.05）;平均骨密度增长情况与非应时治疗组差异显著（P〈0.05）,而与对照组无差异（P〉0.05）。结论：采用冬三月服用左归丸应时治疗原发性骨质疏松症并维持2年以上,不仅服用方便,综合疗效也优于非应时治疗组与西药组。Objective：Zuogui Wan seasonal treatment efficacy for primary osteoporosis would be observed. Methods：68 patients diagnosed as primary osteoporosis in february 2012-october 2013 were randomly divided into three groups,25 patients in seasonal treatment group taking Zuoguiwan in winter,21 patients in non-seasonal treatment group taking Zuogui Wan in other seasons,in the control group,22 diagnosed cases using Fosamax for three months;the second year,each group maintained the original treatment program. After calculating annual symptom scores and measuring the BMD per course of treatment,we can evaluate the treatment efficacy of each group. Results：The symptom scores were decreased significantly in the seasonal treatment group（P0.05）,but the BMD is no difference with the control group after 2 years（P0.05）. Conclusion：Zuogui Wan efficacy in the 2-years seasonal treatment for primary osteoporosis is better than non-seasonal treatment group and western medicine group.

关 键 词：左归丸 原发骨质疏松症 应时 疗效评价 

分 类 号：R714.257[医药卫生—妇产科学]